Copyright
©The Author(s) 2019.
World J Gastrointest Oncol. Jul 15, 2019; 11(7): 509-517
Published online Jul 15, 2019. doi: 10.4251/wjgo.v11.i7.509
Published online Jul 15, 2019. doi: 10.4251/wjgo.v11.i7.509
Table 1 Comparison of patient-derived cancer models
| Cancer cell lines | Xenografts | Organoids | |
| Model system | In vitro | In vivo | In vitro |
| Shape | 2D | 3D | 3D |
| Time prior to drug testing | 1-2 d | 4-8 mo | 10-14 d |
| Cellularity | Clones of single cell | Tumor in microenvironment | Multiple cell types |
| Biological material produced | Abundant | Scarce | Abundant |
| Cost | Low | High | Medium |
| Tumor architecture | None | Represented | Represented |
| Primary tumor represented | No | Yes | Yes |
- Citation: Lin M, Gao M, Cavnar MJ, Kim J. Utilizing gastric cancer organoids to assess tumor biology and personalize medicine. World J Gastrointest Oncol 2019; 11(7): 509-517
- URL: https://www.wjgnet.com/1948-5204/full/v11/i7/509.htm
- DOI: https://dx.doi.org/10.4251/wjgo.v11.i7.509